SCHEMBL4425924

SCHEMBL4425924

Cc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1C(=O)Nc1ccc2cccnc2c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
MAPT P10636 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
TSHR P16473 1/20 0.52
PTPN11 Q06124 1/20 0.48
NAMPT P43490 2/20 0.46
THRB P10828 1/20 0.45
CCNK O75909 1/20 0.45
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CCND3 P30281 1/20 0.45
CDK9 P50750 1/20 0.45
CDK6 Q00534 1/20 0.45
BACE1 P56817 2/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.43
CYP2C19 P33261 1/20 0.42
NOTUM Q6P988 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2420167 0.84 POLB (0.52) MEN1KMT2AMAPTSMN1; SMN2TSHR
SCHEMBL24669340 0.82 MAPT (0.55) MEN1KMT2AMAPTSMN1; SMN2TSHR
SCHEMBL29803543 0.82 MAPT (0.55) MEN1KMT2AMAPTSMN1; SMN2TSHR
SCHEMBL30182291 0.79 MAPT (0.62) MEN1KMT2AMAPTSMN1; SMN2TSHR
SCHEMBL24891763 0.79 MAPT (0.62) MEN1KMT2AMAPTSMN1; SMN2TSHR
SCHEMBL29803595 0.78 MAPT (0.54) MEN1KMT2AMAPTSMN1; SMN2TSHR
SCHEMBL24670693 0.78 MAPT (0.54) MEN1KMT2AMAPTSMN1; SMN2TSHR
SCHEMBL4425930 0.78 MEN1 (0.40) MEN1KMT2AMAPTTHRBPOLB
SCHEMBL2419663 0.78 POLB (0.52) MEN1KMT2AMAPTSMN1; SMN2TSHR
SCHEMBL15557258 0.76 MAPT (0.50) MEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
EP-2033953-A1 Vanilloid receptor modulators Glaxo Group Limited (GB) 2009-03-11 EP disclosed
US-20060142333-A1 Vanilloid receptor modulators MACDONALD GREGOR J 2006-06-29 US disclosed
EP-1480954-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-12-01 EP disclosed
WO-2003068749-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142333-A1 Vanilloid receptor modulators TRPV1, NPSR1, TRPV3 MEN1 3527/4885KMT2A 3992/4885MAPT 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.